Biote Corp. Class A (BTMD) dividends
BTMD on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Biote Corp. Class A dividend: key facts
Own Biote Corp. Class A? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next BTMD dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Results, reports and dividend announcements
- Quarterly report (10-Q) (opens in a new tab) · 9 Nov 2026
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Biote price target lowered to $1.20 from $1.50 at B. Riley9 Nov 2026 · TheFly
B. Riley lowered the firmâs price target on Biote (BTMD) to $1.20 from $1.50 and keeps a Neutral rating on the shares.
- Biote reports Q3 EPS 1c vs 22c last year5 Nov 2026 · TheFly
Reports Q3 revenue $43.3M, consensus $44.01M. âWhile a recent improvement in procedure volume provides early evidence of stabilization in underlying demand, our return to growth is progressing more sl...
- Biote backs FY26 revenue view above $175M, consensus $177.92M5 Nov 2026 · TheFly
Backs FY26 adjusted EBITDA view above $25M.
- Biote Reports Third Quarter 2026 Financial Results5 Nov 2026 · Business Wire
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce...
- Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call22 Oct 2026 · Business Wire
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (âBioteâ or the âCompanyâ), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practi...
- Biote sees FY26 revenue above $175M, consensus $190.61M16 Aug 2026 · TheFly
Sees FY26 adjusted EBITDA above $25M
- Biote reports Q2 EPS (23c) vs 10c last year16 Aug 2026 · TheFly
Reports Q2 revenue $44.2M, consensus $46.08M. âOver the past year Biote (BTMD) has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe...
- Biote price target lowered to $2 from $2.50 at TD Cowen16 Aug 2026 · TheFly
TD Cowen analyst Jonna Kim lowered the firmâs price target on Biote (BTMD) to $2 from $2.50 and keeps a Buy rating on the shares. The firm updated its modelâ¦
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.